Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or TNF-α level in patients with mucocutaneous type of Behcet's disease

Journal of Oral Pathology and Medicine

Volumn 38, Issue 5, 2009, Pages 401-405

  Sun, Andy ^a,b   Wang, Yi Ping ^b,c   Chia, Jean San ^d,e   Liu, Bu Yuan ^a,b   Chiang, Chun Pin ^a,b,c,d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Laboratory of Pharmacology and Toxicology   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d Graduate Institute of Oral Biology   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Behcet's disease; Interleukin 6; Interleukin 8; Levamisole; Mucocutaneous type; Tumour necrosis factor

Indexed keywords

COLCHICINE; INTERLEUKIN 6; INTERLEUKIN 8; LEVAMISOLE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; BEHCET DISEASE; CHEMOLUMINESCENCE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN SYNTHESIS INHIBITION; SCHOOL CHILD; SOLID; TREATMENT DURATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BEHCET SYNDROME; CASE-CONTROL STUDIES; CHILD; COLCHICINE; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LEVAMISOLE; MALE; MIDDLE AGED; REFERENCE VALUES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 65649087829     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00774.x     Document Type: Article

References (42)

1. Sfikakis PP. Behcet's disease: a new target for antitumor necrosis factor treatment. Ann Rheum Dis 2002 61 (Suppl. 2 ii51 3. (Pubitemid 35221714)
2. Kahan A, Hamzaoui K, Ayed K. Abnormalities of T lymphocytes subsets in Behcet's disease demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies. J Rheumatol 1992 19 : 742 6.
3. Mochizuki M, Morita E, Yamamoto S, Yamana S. Characteristics of T cell lines established from skin lesions of Behcet's disease. J Dermatol Sci 1997 15 : 9 13. (Pubitemid 27290642)
4. Charteris DG, Barton K, McCartney AC, Lightman SL. CD4+ lymphocyte involvement in ocular Behcet's disease. Autoimmunity 1992 12 : 201 6.
5. Oztas MO, Onder M, Gurer MA, Bukan N, Sancak B. Serum inerleukin 18 and tumor necrosis factor-alpha levels are increased in Behcet's disease. Clin Exp Dermatol 2005 30 : 61 3. (Pubitemid 40188321)
6. Nagafuchi H, Takeno M, Yoshikawa H, et al. Excessive expression of Txk, a member of the Tec family of tyrosine kinases, contributes to excessive Th1 cytokine production by T lymphocytes in patients with Behcet's disease. Clin Exp Immunol 2005 139 : 363 70. (Pubitemid 40222855)
7. Imamura Y, Kurokawa MS, Yoshikawa H, et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease. Clin Exp Immunol 2005 139 : 371 8. (Pubitemid 40222856)
8. Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behcet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999 42 : 1967 74. (Pubitemid 30257764)
9. Hamzaoui K, Hamzaoui A, Hentati F, et al. Phenotype and functional profile of T cells expressing gamma delta receptor from patients with active Behcet's disease. J Rheumatol 1994 21 : 2301 6.
10. Yamakawa Y, Sugita Y, Nagatani T, et al. Interleukin-6 (IL-6) in patients with Behcet's disease. J Dermatol Sci 1996 11 : 189 95. (Pubitemid 26077181)
11. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002 31 : 205 10.
12. Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease. Mediators Inflamm 2002 11 : 87 93. (Pubitemid 34526411)
13. Adam B, Calikoglu E. Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behcet's disease. J Eur Acad Dermatol Venereol 2004 18 : 318 20. (Pubitemid 38618329)
14. Bardak Y, Aridogan BC. The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behcet's disease with ocular involvement. Ocul Immunol Inflamm 2004 12 : 53 8. (Pubitemid 38406453)
15. Akdeniz N, Esrefoglu M, Keles MS, Karakuzu A, Atasoy M. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease. Ann Acad Med Singapore 2004 33 : 596 9. (Pubitemid 39626965)
16. Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet's disease. Cell Immunol 1992 140 : 410 9.
17. al-Dalaan A, al-Sedairy S, al-Balaa S, et al. Enhanced interleukin 8 secretion in circulation of patients with Behcet's disease. J Rheumatol 1995 22 : 904 7.
18. Mantas C, Direskeneli H, Oz D, Yavuz S, Akoglu T. IL-8 producing cells in patients with Behcet's disease. Clin Exp Rheumatol 2000 18 : 249 51. (Pubitemid 30208272)
19. Alpsoy E, Kodelja V, Goerdt S, Orfanos CE, Zouboulis ChC. Serum of patients with Behcet's disease induces classical (pro-inflammatory) activation of human macrophages in vitro. Dermatology 2003 206 : 225 32. (Pubitemid 36407830)
20. Ben Ahmed M, Houman H, Miled M, Dellagi K, Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behcet's disease. Arthritis Rheum 2004 50 : 2291 5. (Pubitemid 38924408)
21. Itoh R, Takenaka T, Okitsu-Negishi S, Matsushima K, Mizoguchi M. Interleukin 8 in Behcet's disease. J Dermatol 1994 21 : 397 404. (Pubitemid 24231361)
22. Wang LM, Kitteringham N, Mineshita S, et al. The demonstration of serum interleukin-8 and superoxide dismutase in Adamantiades-Behcet's disease. Arch Dermatol Res 1997 289 : 444 7. (Pubitemid 27371049)
23. Zouboulis CC, Katsantonis J, Ketteler R, et al. Adamantiades-Behcet's disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res 2000 292 : 279 84. (Pubitemid 30386437)
24. Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC. Adamantiades-Behcet's disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 2000 201 : 37 9.
25. Freire Ade L, Bertolo MB, de Pinho AJ Jr., Samara AM, Fernandes SR. Increased serum levels of interleukin-8 in polyarteritis nodosa and Behcet's disease. Clin Rheumatol 2004 23 : 203 5. (Pubitemid 38812196)
26. Gur-Toy G, Lenk N, Yalcin B, Aksaray S, Alli N. Serum interleukin-8 as a serologic marker of activity in Behcet's disease. Int J Dermatol 2005 44 : 657 60. (Pubitemid 41179607)
27. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001 358 : 295 6. (Pubitemid 32738970)
28. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology 2001 120 : 995 9. (Pubitemid 32193197)
29. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology 2001 40 : 473 4. (Pubitemid 32409564)
30. Sayinalp N, Ozcebe OI, Ozdemir O, Haznedaroglu IC, Dundar S, Kirazli S. Cytokines in Behcet's disease. J Rheumatol 1996 23 : 321 2. (Pubitemid 26079225)
31. Kosar A, Haznedaroglu S, Karaaslan Y, et al. Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behcet's disease. Rheumatol Int 1999 19 : 11 4. (Pubitemid 30025679)
32. Lewinski U, Mavligib G, Hersh E. Cellular immune modulation after a single high dose of levamisole in patients with carcinoma. Cancer 1980 46 : 2185 94. (Pubitemid 11240584)
33. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998 28 : 48 59. (Pubitemid 28378084)
34. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL)-6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993 20 : 1544 9. (Pubitemid 24027329)
35. Sun A, Chia JS, Chang YF, Chiang CP. Levamisole and Chinese medicinal herbs can modulate the serum interleukin-6 level in patients with recurrent aphthous ulcerations. J Oral Pathol Med 2003 32 : 206 14. (Pubitemid 36604015)
36. Sun A, Chang YF, Chia JS, Chiang CP. Serum interleukin-8 level is a more sensitive marker than serum interleukin-6 level in monitoring the disease activity of recurrent aphthous ulcerations. J Oral Pathol Med 2004 33 : 133 9. (Pubitemid 38250004)
37. Sun A, Wang JT, Chia JS, Chiang CP. Levamisole can modulate the serum tumor necrosis factor-α in patients with recurrent aphthous ulcerations. J Oral Pathol Med 2006 35 : 111 6.
38. Lehner T, Barnes CG. Criteria for diagnosis of Behcet's syndrome. In : Lehner T, Barnes CG, eds. Behçet's syndrome: clinical and immunologic features. London : Academic Press, 1979 4 5.
39. Sun A, Chiang CP, Chiou PS, Wang JT, Liu BY, Wu YC. Immunomodulation by levamisole in patients with recurrent aphthous ulcers or oral lichen planus. J Oral Pathol Med 1994 23 : 172 7.
40. Sun A, Chiang CP. Levamisole and/or Chinese medicinal herbs can modulate the serum level of squamous cell carcinoma associated antigen in patients with erosive oral lichen planus. J Oral Pathol Med 2001 30 : 542 8. (Pubitemid 32943811)
41. Sun A, Chia JS, Chang YF, Chiang CP. Serum interleukin-6 level is a useful marker in evaluating therapeutic effects of levamisole and Chinese medicinal herbs on patients with oral lichen planus. J Oral Pathol Med 2002 31 : 196 203. (Pubitemid 34458418)
42. Sun A, Wang JT, Chia JS, Chiang CP. Serum interleukin-8 level is a more sensitive marker than serum interleukin-6 level in monitoring the disease activity of oral lichen planus. Br J Dermatol 2005 152 : 1187 92. (Pubitemid 40933416)